A5063643675- Glioma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Sarcoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Neuroblastoma Research and Treatments
- Bone Tumor Diagnosis and Treatments
- Cardiac Imaging and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Surgical site infection prevention
- Brain Metastases and Treatment
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Effects of Radiation Exposure
- Cardiovascular Function and Risk Factors
- Global Cancer Incidence and Screening
- Testicular diseases and treatments
- Meningioma and schwannoma management
- Pituitary Gland Disorders and Treatments
- Tumors and Oncological Cases
- BRCA gene mutations in cancer
- Palliative Care and End-of-Life Issues
- Breast Lesions and Carcinomas
- Ear and Head Tumors
University of Florida
2016-2025
Florida College
2016-2025
University of Florida Health
2014-2024
Children's Hospital Colorado
2024
Center for Cancer and Blood Disorders
2024
University of Colorado Anschutz Medical Campus
2024
University of Colorado Denver
2023-2024
Royal Adelaide Hospital
2003-2023
The University of Adelaide
2013-2023
University of Colorado Hospital
2023
Proton therapy offers superior low and intermediate radiation dose distribution compared with photon-based for brain skull base tumors; yet tissue within adjacent to the target volume may receive a comparable dose. We investigated tolerance of pediatric brainstem proton identified prognostic variables.All patients < 18 years old tumors or treated from 2007 2013 were reviewed; 313 who received > 50.4 CGE included in this study. Brainstem toxicity was graded according NCI Common Terminology...
Previous studies of the prognostic importance FOXO1 fusion status in patients with rhabdomyosarcoma (RMS) have had conflicting results. We re-examined risk stratification by adding to traditional clinical factors children localized or metastatic RMS.Data from six COG trials (D9602, D9802, D9803, ARST0331, ARTS0431, ARST0531; two each for low-, intermediate- and high-risk patients) accruing previously untreated RMS 1997 2013 yielded 1727 evaluable patients. Survival tree regression event-free...
Dosimetric studies show that proton therapy can reduce the low/intermediate radiation dose to uninvolved tissue in children with low-grade glioma (LGG). For this reason, LGG is fourth most common pediatric tumor treated therapy, yet clinical outcome data on efficacy and toxicity are limited.We reviewed medical records of 174 (≤21 years old) nonmetastatic enrolled a prospective protocol between 2007 2017. We assessed outcomes analyzed patient, tumor, treatment-related variables.The median age...
Proton therapy can reduce the low and intermediate radiation dose to uninvolved brain tissue in children with intracranial ependymomas, which may improve functional outcomes second malignancies survivors. Accordingly, ependymoma has become most common pediatric tumor treated proton therapy, yet data on efficacy toxicity are limited.Between June 2007 February 2017, 179 (≤21 years old) nonmetastatic grade II/III received at our institution. Median age, 3.5 (range, 0.7-21); 58% were male. Most...
Background. The purpose of this study is to review late toxicity following craniospinal radiation for early-stage medulloblastoma.Material and methods. Between 1963 2008, 53 children with stage M0 (n = 50) or M1 3) medulloblastoma were treated at our institution. median age diagnosis was 7.1 years (range 1.2–18.5). irradiation (CSI) dose 28.8 Gy 21.8–38.4). total dose, including boost, 54 42.4–64.8 Gy). Since 1963, the CSI has been incrementally lowered high-risk boost volume reduced....
In this retrospective study, the authors hypothesized that magnetic resonance imaging (MRI) would alter partial breast irradiation (PBI) eligibility by identifying cancers outside PBI volume compared with mammography alone.Since 2002, MRI was used nonselectively at authors' institution for staging of patients nonmetastatic cancer. Of 450 consecutive invasive cancer, 110 who were eligible identified using criteria outlined National Surgical Adjuvant Breast and Bowel Project B-39/Radiation...
To identify prognostic factors for grade 3 radiation dermatitis following passive-scattering proton therapy breast cancer. This retrospective study included data on 23 (11 post-mastectomy and 12 post-lumpectomy) cancer patients who underwent with the passive scattering technique in our institute from 2012 to 2016. Each patient received 50–50.4 cobalt Gy equivalent (CGE) at 1.8 or 2 CGE per daily fraction. Logistic regression analysis was performed skin toxicity. Receiver operating...
Out-of-field neutron dissemination during double-scattered proton therapy has raised concerns of increased second malignancies, disproportionally affecting pediatric patients due to the proportion body exposed scatter dose and inherent radiosensitivity developing tissue. We sought provide empiric data on incidence early tumors.Between 2006 2019, 1713 consecutive children underwent therapy. Median age at treatment was 9.1 years; 371 were ≤3 years old. Thirty-seven (2.2%) had tumor...
ABSTRACT Background In contrast to adult salivary gland tumors, our institutional guidelines utilize lower radiation doses, smaller target margins, and proton therapy (PT) minimize children's developing skull base anatomy. Herein, we report outcomes of pediatric management approach. Procedures We identified 31 patients with tumors treated PT at institution between 2006 2023. Most common histologies were mucoepidermoid carcinoma ( n = 14), acinic cell 5), adenoid cystic 5). Eight radiographic...
This single-institution report describes long-term disease control and late effects in pediatric patients with low-grade glioma (LGG) following radiotherapy (RT).Twenty-nine LGG were treated photon-based RT from 1970 to 2004 (mean age at time of RT, 9.8 y; range, 0.6 19 y). One patient underwent gross total resection, 25 subtotal resection or biopsy, 3 based on radiographic characteristics alone. Three chemotherapy before RT. The median dose was 54 Gy (range, 40 55 Gy).The follow-up 17.8...
Cardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment cardiotoxicity has not yet developed. The aim this study was describe journey patients who through healthcare system in order establish baseline data inform development and implementation patient-centred, evidence-based pathway. Mixed-methods design with quantitative qualitative components using process...